Short communication: Activation of latent HIV type 1 gene expression by suberoylanilide hydroxamic acid (SAHA), an HDAC inhibitor approved for use to treat cutaneous T cell lymphoma

AIDS Research and Human Retroviruses

Volumn 25, Issue 9, 2009, Pages 883-887

  Edelstein, Leonard C ^a   Micheva Viteva, Sophia ^a   Phelan, Bradley D ^a   Dougherty, Joseph P ^a  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE INHIBITOR; VALPROIC ACID; VIRUS RNA; VIRUS VECTOR; VORINOSTAT;

ARTICLE; CHROMATIN; CUTANEOUS T CELL LYMPHOMA; GENE ACTIVATION; GENE EXPRESSION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; LONG TERMINAL REPEAT; NONHUMAN; NUCLEOSOME; PRIORITY JOURNAL; VIRUS ACTIVATION;

CELL LINE; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, VIRAL; HIV-1; HUMANS; HYDROXAMIC ACIDS; LYMPHOCYTES; PROVIRUSES; VIRUS ACTIVATION; VIRUS LATENCY;

EID: 70349277568     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2008.0294     Document Type: Article

References (27)

1. Chun TW, Davey RT Jr., Ostrowski M, et al.: Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. Nat Med 2000;6:757-761.
2. Davey RT Jr, Bhat N, Yoder C, et al.: HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci USA 1999;96:15109-15114.
3. Finzi D, Blankson J, Siliciano JD, et al.: Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999;5:512-517.
4. Jiang G, Espeseth A, Hazuda DJ, and Margolis DM: c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter. J Virol 2007;81:10914-10923.
5. Tyagi M and Karn J: CBF-1 promotes transcriptional silencing during the establishment of HIV-1 latency. EMBO J 2007;26:4985-4995.
6. Williams SA, Chen LF, Kwon H, Ruiz-Jarabo CM, Verdin E, and Greene WC: NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J 2006;25:139-149.
7. Coull JJ, Romerio F, Sun JM, et al.: The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1. J Virol 2000;74:6790-6799.
8. Imai K and Okamoto T: Transcriptional repression of human immunodeficiency virus type 1 by AP-4. J Biol Chem 2006; 281:12495-12505. (Pubitemid 43855336)
9. He G and Margolis DM: Counterregulation of chromatin deacetylation and histone deacetylase occupancy at the integrated promoter of human immunodeficiency virus type 1 (HIV-1) by the HIV-1 repressor YY1 and HIV-1 activator Tat. Mol Cell Biol 2002;22:2965-2973.
10. Ylisastigui L, Archin NM, Lehrman G, Bosch RJ, and Mar-golis DM: Coaxing HIV-1 from resting CD4 T cells: Histone deacetylase inhibition allows latent viral expression. AIDS 2004;18:1101-1108.
11. Van Lint C, Emiliani S, Ott M, and Verdin E: Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. EMBO J 1996;15:1112-1120.
12. Verdin E, Paras P Jr, and Van Lint C: Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation. EMBO J 1993;12:3249-3259.
13. Lehrman G, Hogue IB, Palmer S, et al.: Depletion of latent HIV-1 infection in vivo: A proof-of-concept study. Lancet 2005;366:549-555.
14. Ances BM, Letendre S, Buzzell M, et al.: Valproic acid does not affect markers of human immunodeficiency virus disease progression. J Neurovirol 2006;12:403-406.
15. Siliciano JD, Lai J, Callender M, et al.: Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. J Infect Dis 2007;195:833-836.
16. Mann BS, Johnson JR, Cohen MH, Justice R, and Pazdur R: FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007;12:1247-1252. (Pubitemid 350106355)
17. Marks PA: Discovery and development of SAHA as an anticancer agent. Oncogene 2007;26:1351-1356.
18. Micheva-Viteva S, Pacchia AL, Ron Y, Peltz SW, and Dougherty JP: Human immunodeficiency virus type 1 latency model for high-throughput screening. Antimicrob Agents Chemother 2005;49:5185-5188.
19. Bhaumik SR, Smith E, and Shilatifard A: Covalent modifi-cations of histones during development and disease patho-genesis. Nat Struct Mol Biol 2007;14:1008-1016.
20. Marks PA and Breslow R: Dimethyl sulfoxide to vorinostat: Development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 2007;25:84-90.
21. Edelstein LC, Lagos L, Simmons M, Tirumalai H, and Ge-linas C: NF-kappa B-dependent assembly of an enhanceo-some-like complex on the promoter region of apoptosis inhibitor Bfl-1/A1. Mol Cell Biol 2003;23:2749-2761.
22. Edelstein LC, Pan A, and Collins T: Chromatin modification and the endothelial-specific activation of the E-selectin gene. J Biol Chem 2005;280:11192-11202.
23. El Kharroubi A, Piras G, Zensen R, and Martin MA: Transcriptional activation of the integrated chromatin-associated human immunodeficiency virus type 1 promoter. Mol Cell Biol 1998;18:2535-2544.
24. Rao S, Procko E, and Shannon MF: Chromatin remodeling, measured by a novel real-time polymerase chain reaction assay, across the proximal promoter region of the IL-2 gene. J Immunol 2001;167:4494-4503.
25. Leoni F, Zaliani A, Bertolini G, et al.: The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cyto-kines. Proc Natl Acad Sci USA 2002;99:2995-3000.
26. Reddy P, Maeda Y, Hotary K, et al.: Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc Natl Acad Sci USA 2004;101:3921-3926.
27. Contreras X, Schweneker M, Chen CS, et al.: Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J Biol Chem 2009;284:6782-6789.